Jane Chao, the co-founder and CEO of Ceribell, holds a Ph.D. in biophysics from Cornell University. Before she joined Ceribell, Jane had a solid history of leadership and success in business. She launched her career as a management consultant with McKinsey & Company, and later made her move into the medical space joining Novartis as their Senior Strategy Manager. She then enjoyed a successful career at Genentech as their Principal Manager of Portfolio Management Strategy.

In 2015, Jane started Ceribell full-time as the CEO, the position she currently holds. She has built and led the Ceribell team from early concept stages to a fully commercial, FDA-cleared, clinically proven, and highly successful commercial product that is changing the standard of care for critically ill patients.

Mat Jachim, VP of Commercial Operations, joined Ceribell in 2022. Throughout his career, Mat has specialized in scaling and operationalizing commercial teams in companies ranging in size from start-ups to Fortune 50 organizations. Prior to joining Ceribell, Mat was the Sr. Director of Commercial Operations at iRhythm Technologies where he successfully implemented strategies to streamline operations, increase sales productivity, and led efforts to provide Cardiac Monitoring in the Primary Care setting. Previously, Mat held positions with Veritas Technologies, Oracle, and Comcast Corp where he held roles in Sales Operations, Marketing Operations and Product Marketing. Mat holds an MBA from Santa Clara University with a specialization in Marketing.

Louisa Daniels has served as General Counsel of Ceribell since August 2023. Ms. Daniels has been practicing law for over 30 years and oversees all legal and compliance matters for Ceribell. Ms. Daniels has a track record of successful execution with both private and public life sciences and technology companies, including in connection with commercial product launches, and resolution of complex litigation, compliance and other corporate matters. Ms. Daniels has worked for several global biopharmaceutical companies in her career. Before Ceribell, Ms. Daniels was Chief Legal Officer and Chief Compliance Officer for Recursion Pharmaceuticals, a clinical-stage company focused on AI-enabled drug discovery, which she helped take public in April 2021. From 2008 to 2021, Ms. Daniels served as Vice President and Assistant General Counsel at Pfizer, where she held various management positions including Chief Counsel for Global Product Development; Global Commercial Operations, Strategy & Portfolio Management; and both BioTherapeutics and PharmaTherapeutics R&D. Prior to Pfizer, she worked as in-house counsel at Elan Pharmaceuticals and Tularik Inc., which was acquired by Amgen during her tenure. Ms. Daniels received a B.A. and J.D. from the University of California, Berkeley and an M.B.A. from the University of California, Irvine (Paul Merage School of Business).